Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index

10Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To investigate whether contralateral parenchymal enhancement (CPE) on MRI during neoadjuvant endocrine therapy (NET) is associated with the preoperative endocrine prognostic index (PEPI) of ER+/HER2− breast cancer. Methods: This retrospective observational cohort study included 40 unilateral ER+/HER2− breast cancer patients treated with NET. Patients received NET for 6 to 9 months with MRI response monitoring after 3 and/or 6 months. PEPI was used as endpoint. PEPI is based on surgery-derived pathology (pT- and pN-stage, Ki67, and ER-status) and stratifies patients in three groups with distinct prognoses. Mixed effects and ROC analysis were performed to investigate whether CPE was associated with PEPI and to assess discriminatory ability. Results: The median patient age was 61 (interquartile interval: 52, 69). Twelve patients had PEPI-1 (good prognosis), 15 PEPI-2 (intermediate), and 13 PEPI-3 (poor). High pretreatment CPE was associated with PEPI-3: pretreatment CPE was 39.4% higher on average (95% CI = 1.3, 91.9%; p =.047) compared with PEPI-1. CPE decreased after 3 months in PEPI-2 and PEPI-3. The average reduction was 24.4% (95% CI = 2.6, 41.3%; p =.032) in PEPI-2 and 29.2% (95% CI = 7.8, 45.6%; p =.011) in PEPI-3 compared with baseline. Change in CPE was predictive of PEPI-1 vs PEPI-2+3 (AUC = 0.77; 95% CI = 0.57, 0.96). Conclusions: CPE during NET is associated with PEPI-group in ER+/HER2− breast cancer: a high pretreatment CPE and a decrease in CPE during NET were associated with a poor prognosis after NET on the basis of PEPI. Key Points: • Change in contralateral breast parenchymal enhancement on MRI during neoadjuvant endocrine therapy distinguished between patients with a good and intermediate/poor prognosis at final pathology. • Patients with a poor prognosis at final pathology showed higher baseline parenchymal enhancement on average compared to patients with a good prognosis. • Patients with an intermediate/poor prognosis at final pathology showed a higher average reduction in parenchymal enhancement after 3 months of neoadjuvant endocrine therapy.

References Powered by Scopus

Fitting linear mixed-effects models using lme4

58486Citations
N/AReaders
Get full text

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

23409Citations
N/AReaders
Get full text

lmerTest Package: Tests in Linear Mixed Effects Models

14500Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Background parenchymal enhancement and uptake as breast cancer imaging biomarkers: A state-of-the-art review

25Citations
N/AReaders
Get full text

The present and future of neoadjuvant endocrine therapy for breast cancer treatment

14Citations
N/AReaders
Get full text

Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ragusi, M. A. A., Loo, C. E., van der Velden, B. H. M., Wesseling, J., Linn, S. C., Beets-Tan, R. G., … Gilhuijs, K. G. A. (2020). Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index. European Radiology, 30(12), 6740–6748. https://doi.org/10.1007/s00330-020-07058-3

Readers over time

‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

75%

Researcher 5

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

82%

Chemical Engineering 1

6%

Pharmacology, Toxicology and Pharmaceut... 1

6%

Neuroscience 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0